Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
1.370
-0.030 (-2.14%)
Apr 29, 2025, 4:00 PM EDT - Market closed

Akari Therapeutics, Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-19.79-10.01-17.75-17.42-17.08
Upgrade
Depreciation & Amortization
0.010000.01
Upgrade
Stock-Based Compensation
2.251.150.740.310.33
Upgrade
Other Operating Activities
-1.56-6.71-5.320.24-0.15
Upgrade
Change in Accounts Payable
5.22-0.94-0.88-0.24-0.25
Upgrade
Change in Other Net Operating Assets
1.320.071.7-1.740.19
Upgrade
Operating Cash Flow
-12.55-16.43-21.5-18.85-16.95
Upgrade
Cash Acquisitions
0.38----
Upgrade
Investing Cash Flow
0.38----
Upgrade
Short-Term Debt Issued
1.03----
Upgrade
Total Debt Issued
1.03----
Upgrade
Short-Term Debt Repaid
-1.86----
Upgrade
Total Debt Repaid
-1.86----
Upgrade
Net Debt Issued (Repaid)
-0.83----
Upgrade
Issuance of Common Stock
11.827.0225.2914.2925.07
Upgrade
Financing Cash Flow
10.997.0225.2914.2925.07
Upgrade
Foreign Exchange Rate Adjustments
-00.010.11-0.140.2
Upgrade
Net Cash Flow
-1.19-9.413.89-4.698.32
Upgrade
Free Cash Flow
-12.55-16.43-21.5-18.85-16.95
Upgrade
Free Cash Flow Per Share
-1.05-3.36-6.89-8.78-10.73
Upgrade
Levered Free Cash Flow
3.91-16.74-6.04-11.31-11.96
Upgrade
Unlevered Free Cash Flow
4.06-16.74-6.04-11.31-11.96
Upgrade
Change in Net Working Capital
-12.217.39-7.650.871.06
Upgrade
Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q